Abstract
Muramyl peptides (MPs) possess immunostimulatory, pyrogenic and somnogenic activities. The structural requirements of MPs for each of these activities are different though certain MPs, e.g. muramyl dipeptide (NAM-L-ala-D-isogln) possess all three activities. Several MPs are proposed for use as immune adjuvants; somnogenic and pyrogenic activities would be considered adverse side effects of such compounds. We report here that some of the putative adjuvants, GIF101, WG209 and MDP-threonine lack somnogenic and pyrogenic activities. Current results also expand our understanding of the structural requirements for these activities. Major findings are that the addition of the dipeptide L-ala-D-isogln to NAG-NAM-L-ala-D-isogln blocks the activity of the latter compound and that the amino sugar moiety of MPs, NAM, is unnecessary for somnogenic and pyrogenic activity. © 1994.
Cite
CITATION STYLE
Johannsen, L., Orál, F., Kapás, L., Kovalzon, V., & Krueger, J. M. (1994). Somnogenic activity of muramyl peptide-derived immune adjuvants. International Journal of Immunopharmacology, 16(2), 109–116. https://doi.org/10.1016/0192-0561(94)90066-3
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.